Nektar Therapeutics (NKTR) Restructuring Costs (2022 - 2026)

Nektar Therapeutics' Restructuring Costs history runs 5 years deep, the most recent figure standing at $796000.0 for Q1 2026.

• In Q1 2026, Restructuring Costs rose 371.01% year-over-year to $796000.0; the TTM figure through Mar 2026 stood at $10.0 million (down 33.01% YoY), while the FY2025 annual figure was $9.3 million, down 40.45% from the prior year.
• Restructuring Costs for Q1 2026 stood at $796000.0, down from $8.6 million in the prior quarter.
• The five-year high for Restructuring Costs was $106.0 million in Q2 2022, with the low at -$41.2 million in Q4 2023.
• The 5-year median for Restructuring Costs is $1.4 million (2023), against an average of $7.3 million.
• The sharpest annual moves came in 2023 and 2024: Restructuring Costs tumbled 455.85% in 2023, then surged 880.01% in 2024.
• Nektar Therapeutics' Restructuring Costs stood at $11.6 million in 2022, then sank by 455.85% to -$41.2 million in 2023, then surged by 103.3% to $1.4 million in 2024, then jumped by 530.51% to $8.6 million in 2025, then slumped by 90.72% to $796000.0 in 2026.
• Business Quant data shows NKTR's Restructuring Costs at $796000.0 in Q1 2026, $8.6 million in Q4 2025, and $140000.0 in Q3 2025.